Advertisement

Outcome of dogs with high-grade soft tissue sarcomas treated with and without adjuvant doxorubicin chemotherapy: 39 cases (1996–2004)

Kim A. SeltingDepartment of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Kim A. Selting in
Current site
Google Scholar
PubMed
Close
 DVM, MS, DACVIM
,
Barbara E. PowersVeterinary Diagnostic Laboratory, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Barbara E. Powers in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVP
,
Laura J. ThompsonAnimal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Laura J. Thompson in
Current site
Google Scholar
PubMed
Close
 BS
,
Elise MittlemanAnimal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.
Present address is Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104-6010.

Search for other papers by Elise Mittleman in
Current site
Google Scholar
PubMed
Close
 DVM
,
Jeff W. TylerDepartment of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Jeff W. Tyler in
Current site
Google Scholar
PubMed
Close
 DVM, PhD, DACVIM
,
Mary H. LaffertyAnimal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Mary H. Lafferty in
Current site
Google Scholar
PubMed
Close
, and
Stephen J. WithrowAnimal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523.

Search for other papers by Stephen J. Withrow in
Current site
Google Scholar
PubMed
Close
 DVM, DACVIM, DACVS

Abstract

Objective—To examine the effect of adjuvant doxorubicin chemotherapy on outcome in dogs with highgrade (grade 3) soft tissue sarcomas (HGSTSs).

Design—Retrospective case series.

Animals—39 dogs.

Procedures—Medical records of dogs with HGSTSs were reviewed. Dogs treated with surgery alone or receiving single-agent doxorubicin chemotherapy postoperatively were included in the study. Owners and referring veterinarians were contacted for followup information. Slides from histologic sections were reviewed to confirm the diagnosis of HGSTSs. Cases in which follow-up examination was not performed and radiation therapy or chemotherapy other than doxorubicin was administered were excluded.

Results—39 dogs met inclusion criteria. Twenty-one dogs received adjuvant doxorubicin. Tumor-, patient-, and treatment-related variables were not significantly associated with measured outcomes including local, metastatic, and overall disease-free intervals as well as survival time. Overall median disease-free interval was 724 days with a median survival time of 856 days for all dogs.

Conclusions and Clinical Relevance—Adjuvant doxorubicin-based chemotherapy did not benefit this population of dogs with HGSTSs. Outcome for visceral HGSTSs was similar to that of nonvisceral HGSTSs in these cases. (J Am Vet Med Assoc 2005;227:1442–1448)

Abstract

Objective—To examine the effect of adjuvant doxorubicin chemotherapy on outcome in dogs with highgrade (grade 3) soft tissue sarcomas (HGSTSs).

Design—Retrospective case series.

Animals—39 dogs.

Procedures—Medical records of dogs with HGSTSs were reviewed. Dogs treated with surgery alone or receiving single-agent doxorubicin chemotherapy postoperatively were included in the study. Owners and referring veterinarians were contacted for followup information. Slides from histologic sections were reviewed to confirm the diagnosis of HGSTSs. Cases in which follow-up examination was not performed and radiation therapy or chemotherapy other than doxorubicin was administered were excluded.

Results—39 dogs met inclusion criteria. Twenty-one dogs received adjuvant doxorubicin. Tumor-, patient-, and treatment-related variables were not significantly associated with measured outcomes including local, metastatic, and overall disease-free intervals as well as survival time. Overall median disease-free interval was 724 days with a median survival time of 856 days for all dogs.

Conclusions and Clinical Relevance—Adjuvant doxorubicin-based chemotherapy did not benefit this population of dogs with HGSTSs. Outcome for visceral HGSTSs was similar to that of nonvisceral HGSTSs in these cases. (J Am Vet Med Assoc 2005;227:1442–1448)